| 1 |
34420059 | Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab. | 2022 Apr |
2 |
| 2 |
34933901 | Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. | 2022 Apr 1 |
2 |
| 3 |
35092538 | Examining the prevalence of homologous recombination repair defects in ER+ breast cancers. | 2022 Apr |
1 |
| 4 |
32970266 | External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit? | 2021 Mar |
1 |
| 5 |
33569679 | Sensitive sandwich-type voltammetric immunosensor for breast cancer biomarker HER2 detection based on gold nanoparticles decorated Cu-MOF and Cu2ZnSnS4 NPs/Pt/g-C3N4 composite. | 2021 Feb 10 |
1 |
| 6 |
33916671 | Au@Pt Core-Shell Nanoparticle Bioconjugates for the Therapy of HER2+ Breast Cancer and Hepatocellular Carcinoma. Model Studies on the Applicability of 193mPt and 195mPt Radionuclides in Auger Electron Therapy. | 2021 Apr 3 |
1 |
| 7 |
33932503 | Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. | 2021 Aug |
1 |
| 8 |
34293698 | Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways. | 2021 Nov 15 |
1 |
| 9 |
31815582 | Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201. | 2020 Feb 10 |
1 |
| 10 |
32235305 | Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry. | 2020 Mar 29 |
1 |
| 11 |
32735623 | Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. | 2020 |
1 |
| 12 |
32750194 | A Multi-action PtIV Conjugate with Oleate and Cinnamate Ligands Targets Human Epithelial Growth Factor Receptor HER2 in Aggressive Breast Cancer Cells. | 2020 Nov 16 |
1 |
| 13 |
32984690 | Red-Fluorescent Pt Nanoclusters for Detecting and Imaging HER2 in Breast Cancer Cells. | 2020 Sep 22 |
2 |
| 14 |
30124494 | Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer. | 2019 Jan |
2 |
| 15 |
30504425 | NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer. | 2019 Mar 1 |
1 |
| 16 |
30909992 | [Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung
Adenocarcinoma]. | 2019 Mar 20 |
4 |
| 17 |
31409079 | Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno. | 2019 Summer |
1 |
| 18 |
30326862 | Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. | 2018 Oct 16 |
1 |
| 19 |
28944120 | Treatment of Male Breast Cancer by Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Response Prediction Using Novel Optical Tomography Imaging: A Case Report. | 2017 Jul 17 |
1 |
| 20 |
28989055 | Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment. | 2017 Dec 28 |
1 |
| 21 |
29254172 | Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. | 2017 Nov 24 |
1 |
| 22 |
26588239 | Evaluation of TOP2A as a Predictive Marker for Endometrial Cancer With Taxane-Containing Adjuvant Chemotherapy. | 2016 Feb |
1 |
| 23 |
26693899 | Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. | 2016 Jan |
2 |
| 24 |
27016235 | Germline mutations of the DNA repair pathways in uterine serous carcinoma. | 2016 Apr |
1 |
| 25 |
27044931 | Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. | 2016 Jun 20 |
1 |
| 26 |
25467313 | Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab. | 2015 Feb |
2 |
| 27 |
25602630 | PRP4K is a HER2-regulated modifier of taxane sensitivity. | 2015 |
1 |
| 28 |
26099969 | Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. | 2015 Aug |
1 |
| 29 |
26186063 | Trastuzumab-mediated selective delivery for platinum drug to HER2-positive breast cancer cells. | 2015 Oct |
1 |
| 30 |
26211591 | Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery. | 2015 Jul |
2 |
| 31 |
26359224 | Advancing pharmacological treatment options for advanced gastric cancer. | 2015 |
1 |
| 32 |
23680713 | Esophageal carcinoma: are modern targeted therapies shaking the rock? | 2013 Jul |
1 |
| 33 |
22396490 | Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. | 2012 May 1 |
1 |
| 34 |
22990650 | Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. | 2012 Oct 9 |
1 |
| 35 |
23197882 | Advanced gastric cancer: is there enough evidence to call second-line therapy standard? | 2012 Nov 28 |
1 |
| 36 |
21135055 | An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. | 2011 Jul |
1 |
| 37 |
21985855 | Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). | 2011 |
1 |
| 38 |
20417484 | Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. | 2010 Aug |
6 |
| 39 |
19258951 | Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. | 2009 Jan |
4 |
| 40 |
19028616 | The Renaissance of platinum-based chemotherapy for metastatic breast cancer. | 2008 Oct |
1 |
| 41 |
15865102 | Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours. | 2005 Mar-Apr |
1 |
| 42 |
14729645 | Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. | 2004 Jan 1 |
2 |
| 43 |
15545967 | TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. | 2004 Nov 29 |
1 |
| 44 |
15685824 | Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. | 2004 Dec |
1 |
| 45 |
19780241 | Breast cancer: review of platinum-based cooperative group trials. | 2004 Sep |
1 |
| 46 |
12694661 | Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy. | 2003 Apr |
3 |
| 47 |
11899413 | Platinum compounds in the treatment of advanced breast cancer. | 2001 Oct |
6 |
| 48 |
9475194 | Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. | 1998 Jan |
1 |
| 49 |
9383735 | Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. | 1997 Nov |
1 |
| 50 |
8652251 | An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. | 1995 Dec |
1 |